IPL stands for intense pulsed light. The technology delivers controlled pulses of broad-spectrum light to the area below and around the eyes. OptiLight® was developed specifically for dry eye management related to meibomian gland dysfunction. In the United States, it is FDA-approved for improving signs of dry eye disease due to MGD in appropriate patients aged 22 and older.
The goal of treatment is not simply to add moisture to the eyes. IPL is used to address inflammation associated with MGD and support a healthier environment for the meibomian glands and tear film.
